aim
studi
indic
chloroquin
cq
show
antagon
vitro
coronavirus
envelop
positivesens
singlestrand
rna
virus
belong
famili
coronavirida
broadli
distribut
human
vertebr
eventu
caus
damag
digest
respiratori
even
multipl
system
decemb
seri
pneumonia
case
unknown
etiolog
appear
wuhan
hubei
china
sequenc
analysi
throat
swab
sampl
electron
microscop
observ
indic
novel
coronaviru
name
formerli
known
coronaviru
diseas
caus
confirm
obviou
humantohuman
characterist
march
two
hundr
thousand
confirm
case
identifi
global
total
death
epidem
spread
mani
countri
pose
sever
threat
global
health
therefor
urgent
develop
effect
drug
recent
public
result
show
activ
chloroquin
cq
vitro
expert
research
also
recommend
efficaci
antimalari
drug
patient
us
food
drug
administr
fda
work
investig
use
cq
deriv
cq
hydroxychloroquin
hcq
similar
therapeut
effect
fewer
advers
effect
base
characterist
immun
regul
antithrombot
activ
inflamm
improv
hcq
routin
use
clinic
treatment
system
lupu
erythematosu
sle
howev
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
efficaci
hcq
remain
unknown
interestingli
followup
survey
found
none
sle
patient
took
longterm
oral
hcq
confirm
infect
appear
relat
symptom
addit
among
patient
diagnos
pneumonia
hospit
none
receiv
hcq
treatment
admiss
predict
use
hcq
infect
one
clinic
research
registr
unit
china
aim
investig
effici
hcq
patient
studi
clinic
research
protocol
review
approv
ethic
committe
renmin
patient
met
trial
criteria
randomli
assign
two
group
receiv
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
standard
treatment
oxygen
therapi
antivir
agent
antibacteri
agent
immunoglobulin
without
corticosteroid
patient
hcq
treatment
group
receiv
addit
oral
hcq
hydroxychloroquin
sulfat
tablet
shanghai
pharma
mgd
mgbid
day
figur
patient
control
group
standard
treatment
random
perform
computergener
list
stratifi
site
treatment
assign
confirm
correct
admiss
criteria
neither
research
perform
patient
awar
treatment
assign
pulmonari
recoveri
defin
three
level
exacerb
unchang
improv
moder
improv
less
pneumonia
absorb
mean
significantli
improv
data
describ
mean
standard
deviat
sd
n
ttest
test
use
compar
differ
two
group
twosid
pvalu
less
consid
statist
signific
statist
analys
perform
use
graphpad
prism
version
patient
identifi
enrol
studi
none
quit
figur
shown
tabl
patient
age
year
old
male
femal
patient
randomli
assign
two
group
signific
differ
age
sex
distribut
two
group
patient
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
effect
cq
patient
regist
trial
chictr
chose
hcq
sulfat
phosphat
salt
cq
intervent
agent
data
studi
reveal
day
hcq
treatment
symptom
patient
significantli
reliev
manifest
shorten
recoveri
time
cough
fever
time
larger
proport
patient
pulmonari
inflammatori
partial
absorb
hcq
treatment
group
indic
immun
modul
antiinflammatori
properti
hcq
nonmalari
diseas
present
multipl
action
hcq
regul
proinflammatori
cytokin
eg
tumor
necrosi
antioxid
activ
also
promot
wide
perform
rheumat
diseas
sle
accord
current
research
higher
proinflammatori
cytokin
storm
exist
patient
sever
critic
ill
eventu
affect
prognosi
antibodi
blocker
transfus
convalesc
plasma
therapi
appli
counteract
cytokin
storm
therefor
antivir
autoimmun
regul
effect
hcq
protector
infect
present
studi
reduc
risk
progress
sever
ill
patient
hcq
treatment
also
explain
intervent
effect
hcq
patholog
process
although
hcq
proven
effect
advantag
inexpens
easili
access
potenti
detriment
effect
viral
diseas
must
also
taken
serious
retinopathi
one
major
advers
reaction
longterm
therapi
hcq
besid
patient
rheumatoid
diseas
treat
hcq
occasion
experi
arrhythmia
rare
advers
reaction
caus
hcq
includ
gastrointestin
reaction
cramp
liver
dysfunct
itch
headach
dizzi
insomnia
peripher
neuropathi
fortun
decid
individu
treatment
plan
scientif
monitor
advers
reaction
time
avoid
overdos
shortterm
applic
hcq
rel
safe
despit
small
number
case
potenti
hcq
treatment
partial
confirm
consid
better
option
present
promis
practic
appli
hcq
reason
manag
howev
largescal
clinic
basic
research
still
need
clarifi
specif
mechan
continu
optim
treatment
plan
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
abbrevi
hcq
hydroxychloroquin
figur
studi
flow
diagram
abbrevi
sever
acut
respiratori
syndrom
coronaviru
hcq
hydroxychloroquin
ct
comput
tomographi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
